Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001140361-23-042097
Filing Date
2023-08-31
Accepted
2023-08-31 17:17:40
Documents
1
Group Members
FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT V, LLCFORESITE CAPITAL OPPORTUNITY FUND V, L.P.FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SC 13D/A brhc20058275_sc13da.htm SC 13D/A 195208
  Complete submission text file 0001140361-23-042097.txt   197088
Mailing Address 2173 SALK AVENUE SUITE 250, PMB#052 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 250, PMB#052 CARLSBAD CA 92008 415-649-8758
PARDES BIOSCIENCES, INC. (Subject) CIK: 0001822711 (see all company filings)

EIN.: 852696306 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-93142 | Film No.: 231229493
SIC: 2834 Pharmaceutical Preparations

Mailing Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111 415 877 4887
FS Development Holdings II, LLC (Filed by) CIK: 0001822712 (see all company filings)

EIN.: 852696944 | State of Incorp.: DE
Type: SC 13D/A